Krystal Biotech Inc to Disclose An interim Clinical Update Transcript
Thank you for standing by and welcome to Krystal Biotech's clinical update call for cystic fibrosis program KB407. (Operator Instructions) As a reminder, today's conference is being recorded.
I would now like to hand the conference over to your host, Stephane Paquette, Vice President of Corporate Development.
Good afternoon and thank you all for joining today's call. Earlier today, we announced positive interim clinical results for Krystal Biotech's cystic fibrosis program KB407, including molecular confirmation of wild-type CFTR protein expression in patient's lungs. The press release is available on our website at www.krystalbio.com. Both the press release and today's presentation have also been filed as an 8-K with the SEC.
Joining me today will be Krish Krishnan, Chairman and Chief Executive Officer; Suma Krishnan, President of Research and Development; Trevor Parry, Vice President of Product
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
